Navigation Links
New findings further clarify breast cancer risk with hormone therapy
Date:8/10/2010

PHILADELPHIA A new analysis of the California Teachers Study, which analyzed hormone replacement therapy use among 2,857 women for almost 10 years, underscores the need for personalized risk-benefit discussions before women begin hormone therapy.

"This is evidence that the story is complicated," said Tanmai Saxena, an M.D./Ph.D. student at the Keck School of Medicine at the University of Southern California. "The benefits of hormone therapy for relief of postmenopausal symptoms among women are clear, but the risks are more complicated than we had previously thought."

In a report published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, Saxena and colleagues found that compared with women who had never used hormone therapy, women who used estrogen therapy for more than 15 years had a 19 percent greater risk of developing breast cancer.

Women who used combined therapy with estrogen plus progestin for 15 or more years had an 83 percent greater risk. Breast cancer risk was highest among women who used the combination regimen.

Breast cancer risk seemed dependent on body mass index (BMI). Those with a BMI less than 30 appeared to have an increased risk of breast cancer with combined hormone therapy; the risk was strongest among women with BMI less than 25. In contrast, obese women (i.e., BMI of 30 or more) had no further increase in risk associated with using combined hormone therapy.

Finally, the risk of breast cancer was confined to tumors that were positive for both estrogen and progestin receptors. The risk was somewhat weaker for HER2 negative tumors.

Susan Hankinson, Sc.D., professor of medicine at Harvard Medical School, said the findings underscore the reality that even following the Women's Health Initiative (WHI) trial and large prospective studies including the California Teachers Study, there are still questions that remain.

"These results add new evidence that risk does vary by other personal characteristics. However, for now, the public health message remains essentially the same. There is an increased risk of breast cancer from hormone use, and further studies will address the question of how specific that risk is," said Hankinson, who is a senior editor of Cancer Epidemiology, Biomarkers & Prevention.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert  

Related medicine news :

1. Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts
2. U. Iowa biologists publish findings on cell interactions
3. Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course
4. Tel Aviv University Fertility Research Confirms New York Center's DHEA Findings
5. Fresh findings about chickenpox could lead to better blood tests
6. Brain MRI in children: Incidental findings yield disclosure dilemmas for doctors, patients
7. VARI findings could help diagnose and treat liver cancer
8. Findings suggest optimal dose
9. Those with allergic asthma face double trouble during flu season, UT Southwestern findings suggest
10. Research findings underscore needed action to safeguard lungs of young cancer survivors
11. Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New findings further clarify breast cancer risk with hormone therapy
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: